Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
DMAA
Upturn stock ratingUpturn stock rating

Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)

Upturn stock ratingUpturn stock rating
$10.28
Last Close (24-hour delay)
Profit since last BUY0%
upturn advisory
Consider higher Upturn Star rating
BUY since 4 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: DMAA (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

0 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 4
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 5.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -
52 Weeks Range 9.95 - 10.27
Updated Date 05/1/2025
52 Weeks Range 9.95 - 10.27
Updated Date 05/1/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating -
Shares Outstanding -
Shares Floating -
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

Drugs Made In America Acquisition Corp. Ordinary Shares

stock logo

Company Overview

overview logo History and Background

Drugs Made In America Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It was founded in 2021.

business area logo Core Business Areas

  • Special Purpose Acquisition Company (SPAC): Drugs Made In America Acquisition Corp. focuses on identifying and acquiring a target company. It does not have specific operations until it completes an acquisition.

leadership logo Leadership and Structure

The company is led by a management team focused on identifying acquisition targets, typically in the healthcare or pharmaceutical sector. The organizational structure is typical of a SPAC, with a board of directors and executives responsible for deal sourcing and execution.

Top Products and Market Share

overview logo Key Offerings

  • Blank Check Acquisition Target: The company's primary offering is the potential acquisition of an operating business. Market share is not applicable as it is a SPAC. Competitors include other SPACs searching for targets.

Market Dynamics

industry overview logo Industry Overview

The SPAC market is characterized by high competition and regulatory scrutiny. Success depends on identifying attractive acquisition targets and completing deals on favorable terms.

Positioning

Drugs Made In America Acquisition Corp. is positioned as a vehicle for a target company to go public. Competitive advantages depend on the team's deal-sourcing abilities and sector expertise.

Total Addressable Market (TAM)

The TAM is the total value of potential acquisition targets. Drugs Made In America Acquisition Corp.'s positioning with respect to TAM depends on its ability to identify and acquire a suitable target company.

Upturn SWOT Analysis

Strengths

  • Experienced management team
  • Dedicated capital for acquisition
  • Flexibility in deal structure

Weaknesses

  • No operating history
  • Dependence on finding suitable target
  • Potential for shareholder dilution

Opportunities

  • Acquisition of high-growth company
  • Leveraging market trends
  • Creating shareholder value

Threats

  • Increased competition from other SPACs
  • Regulatory changes
  • Economic downturn

Competitors and Market Share

competitor logo Key Competitors

Competitive Landscape

The competitive landscape is defined by the number of SPACs searching for targets and the attractiveness of available companies.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is not applicable prior to an acquisition.

Future Projections: Future projections depend on the target company's performance.

Recent Initiatives: Recent initiatives involve deal sourcing and due diligence.

Summary

Drugs Made In America Acquisition Corp. is a special purpose acquisition company aiming to identify and acquire a company, likely in the pharmaceutical industry. The companyu2019s success hinges on its ability to find and close a deal on favorable terms. It faces competition from other SPACs. The team needs to secure a promising target and needs to be weary of the increasing scrutiny of the SPAC process.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC filings
  • Company press releases

Disclaimers:

This analysis is based on limited publicly available information and is subject to change. It is not financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Drugs Made In America Acquisition Corp. Ordinary Shares

Exchange NASDAQ
Headquaters Fort Lauderdale, FL, United States
IPO Launch date 2025-02-25
CEO & Executive Chairman Ms. Lynn Stockwell
Sector Financial Services
Industry Shell Companies
Full time employees -
Full time employees -

Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.